Introduction Characterizing Peptides in PLGA Microsphere and Depot Formulations requires sophisticated orthogonal analytical methodologies to assess complex drug release kinetics, […]
Introduction The Immunogenicity Risk Assessment of Peptide Impurities represents a critical regulatory evaluation framework established by the U.S. Food and
Immunogenicity Risk Assessment of Peptide Impurities in Generic Synthetic Peptide ANDAs Read More »
Introduction: An Insulin Glargine Biosimilar PK Comparability Study is a core part of the evidence showing that a proposed insulin
Introduction Assessing a Contract Development and Manufacturing Organization (CDMO) demands a systematic review of its technical capabilities, regulatory compliance, quality
What Questions Should You Ask a CDMO Before Signing a Contract? Read More »
Introduction CDMO services for Lipid Nanoparticle (LNP) Formulation and Characterization offer specialized contract development, scalable microfluidic manufacturing, and orthogonal analytical
Lipid Nanoparticle (LNP) Formulation and Characterization Services at a CDMO Read More »
Introduction CDMO Contract Models Explained: Contract Development and Manufacturing Organization (CDMO) contract models establish the legal, operational, and financial frameworks
CDMO Contract Models Explained: FTE, Fee-for-Service, and Milestone-Based Pricing Read More »
Introduction: Bioanalytical Method Development for Oligonucleotide Therapeutics is the process of building and validating a quantitative assay that measures an
Introduction: MALDI-TOF mass spectrometry for peptide characterization is widely used to determine peptide molecular mass, support identity confirmation, and evaluate
Introduction PEGylated Peptide Characterization represents a comprehensive analytical framework designed to assess batch-to-batch consistency, chemical integrity, structural conformation, and purity
PEGylated Peptide Characterization: PEG Heterogeneity, Attachment Site and Purity Read More »
Introduction Non-enzymatic Deamidation and Aspartate Isomerization in Therapeutic Peptides are significant chemical degradation pathways that can modify peptide backbone structure,
